Hengrui Medicine gets CSRC nod for HK share issuance

Jiangsu Hengrui Medicine (SSE:600276) announced it has obtained a filing notification from the China Securities Regulatory Commission (CSRC) regarding its planned issuance of overseas listed foreign shares (H shares) in Hong Kong. The company intends to issue no more than 815,094,600 ordinary shares for listing on the Hong Kong Stock Exchange. The CSRC's notification requires Hengrui Medicine to report any significant developments during the issuance process and to provide a post-issuance report within 15 working days of completion. The company must renew its filing materials if the offering is not completed within 12 months. The company also cautioned investors that the issuance is still subject to approvals from Hong Kong regulators and exchanges and carries investment risks.